2,271,755 Shares in Kestra Medical Technologies, Ltd. $KMTS Bought by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. acquired 2,271,755 shares of Kestra Medical Technologies, Ltd. in the 1st quarter, worth approximately $56.6 million, which gives them a 4.42% ownership stake.
• Analysts have a consensus price target of $27.33 for Kestra Medical Technologies, with five analysts rating the stock as a Buy and one as a Hold.
• The stock currently trades at $18.58, showing a 52-week range from $13.25 to $26.15, and Wells Fargo recently lowered its target price from $28.00 to $27.00 while maintaining an "overweight" rating.

T. Rowe Price Investment Management Inc. acquired a new position in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 2,271,755 shares of the company's stock, valued at approximately $56,613,000. T. Rowe Price Investment Management Inc. owned about 4.42% of Kestra Medical Technologies as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth about $210,000. Russell Investments Group Ltd. acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter valued at about $457,000. Caas Capital Management LP acquired a new position in Kestra Medical Technologies in the first quarter worth about $1,470,000. Jennison Associates LLC bought a new position in Kestra Medical Technologies during the first quarter worth about $1,869,000. Finally, TD Asset Management Inc bought a new stake in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $2,306,000.

Analyst Ratings Changes

Separately, Wells Fargo & Company dropped their price target on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $27.33.

Kestra Medical Technologies Stock Down 0.7%

Shares of KMTS stock traded down $0.12 on Thursday, reaching $17.88. The stock had a trading volume of 20,578 shares, compared to its average volume of 266,922. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.72 and a current ratio of 6.72. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $26.15. The stock's 50-day moving average price is $16.17.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.